Loading...

AYTU AYTU BIOPHARMA INC Company Mergers 8-K Filing

YT B

YT

AYTU BIOPHARMA INC

(AYTU)

2025 8-K

Stockholder Meeting Results

Quarterly Financial Results

Financial Results Announcement

Debt Restructuring

Investor Meetings

Product Overview

Equity Offerings

Rights Offerings

Financial Statements

Court Settlement Hearing

Management Changes

Earnings Announcement

Sale of Consumer Health Bus...

Annual Meeting of Stockholders

Loan Agreement Amendment

Agreement with Halo Pharmac...

Results of Operations and F...

Resignation of COO

Earnings Release

Agreement Announcement

Securities Purchase Agreeme...

Annual Meeting of Stockholders

Earnings Report

Sublease Agreement

FDA Approval and Study Comp...

Discussions for Strategic T...

Loan Agreement Amendment

Earnings Reports

Financial Restatement

Management Agreements Amended

Compliance with Nasdaq List...

Reverse Stock Split

External Links:

On June 5, 2025, Aytu BioPharma, Inc. signed an Exclusive Commercialization Agreement to market EXXUA™ (gepirone) extended release tablets for Major Depressive Disorder, which is projected to launch in late 2025 after an upfront payment of $3 million, with additional milestone payments based on sales performance.

AI Assistant

AYTU BIOPHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.